Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

• heart rate (HR) [ Time Frame: 56 days ] [ Designated as safety issue: Yes ]
  Through standard 12-lead ECGs assess the effect BIA 9-1067 on heart rate (HR), uncorrected QT, QTcF, QTcB, PR, and QRS intervals, and ECG waveform morphology
• QTcI, QTcB, and QTcF to plasma concentrations of BIA 9 1067 [ Time Frame: 56 days ] [ Designated as safety issue: Yes ]
• Number of Adverse Events [ Time Frame: 56 days ] [ Designated as safety issue: Yes ]
  assessment of safety and tolerability

The purpose of this study is to evaluate the effect of BIA 9-1067 on the cardiac repolarization in adult healthy men and women volunteers.

Single-centre, randomized, double-blind, placebo-controlled and open-label active-controlled, 4-period crossover trial in healthy male and female subjects

• Drug: BIA 9-1067
  50 mg and 800 mg of BIA 9-1067 (single-dose)
• Drug: Placebo
  single-dose
• Drug: moxifloxacin
  400 mg moxifloxacin (single-dose)

• Experimental: BIA 9-1067
  Intervention: Drug: BIA 9-1067
• Placebo Comparator: Placebo
  Intervention: Drug: Placebo
• Active Comparator: moxifloxacin
  Intervention: Drug: moxifloxacin

Inclusion Criteria:

• A signed and dated informed consent form before any study-specific screening procedure was performed,
• Healthy male or female 18 to 55 years of age. Women had to be postmenopausal (more than 12 months since last period); surgically sterile (hysterectomy or tubal ligation or bilateral oophorectomy at least 6 months prior to enrollment); using an intrauterine device; a non-hormonal double barrier contraceptive method (i.e., diaphragm or spermicide plus male condom) for the duration of the trial and with a negative pregnancy test at screening and upon each check-in to the study facility,
• Had a BMI within the range of 18-30 kg/m2,
• Able to communicate effectively with the study personnel,
• Had no significant disease or abnormal laboratory values as determined by medical history, physical examination or laboratory evaluations, conducted at the screening visit and on admission to the clinic,
• Had a normal 12-lead electrocardiogram, without any clinically significant abnormalities of rate, rhythm or conduction,
• Non-smokers or ex-smokers for at least 3 months,
• Adequately informed of the nature and risks of the study and gave written informed consent prior to study entry.

Exclusion Criteria:

• Known hypersensitivity or allergy to moxifloxacin, BIA 9-1067 or related compounds such as tolcapone or entacapone,
• Women who were pregnant or breastfeeding,
• Any disease or condition (medical or surgical) which, in the opinion of the Investigator, might have compromised the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that might have interfered with the absorption, distribution, metabolism or excretion of study drug, or would have placed the subject at increased risk,
• A sustained supine systolic blood pressure > 140 mmHg or < 100 mmHg or a diastolic blood pressure > 95 mmHg at screening or baseline,
• A resting ECG heart rate of < 50 bpm or > 100 bpm,
• An abnormal screening ECG indicating a second- or third-degree AV block, or one or more of the following: QRS > 110 milliseconds (ms), QTc (Fridericia correction) > 450 ms for male and 470 ms for females, PR interval > 240 ms. Any rhythm other than sinus rhythm, which was interpreted by the Investigator to be clinically significant,
• The presence of abnormal laboratory values which were considered clinically significant by the Investigator,
• Positive screen for Hepatitis B (HbsAg, Hepatitis B Surface Antigen), Hepatitis C (anti HCV, Hepatitis C Antibody), or HIV (anti-HIV 1/2),
• Received an investigational drug within a period of 30 days prior to enrolment in the study,
• Received any drug therapy, excluding hormonal contraceptives, within 2 weeks prior to administration of the first dose of any study-related treatment. This exclusion was extended to 4 weeks for any drugs known to induce or inhibit hepatic drug metabolism,
• Consumption of alcohol within 48 hours prior to dose administration or during any inpatient period,
• A positive urine drug screen including or a positive alcohol breath test,
• Any history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction,
• A history of difficulty with donating blood,
• Donated blood or blood products within 45 days prior to enrollment,
• History of tendonitis or tendon rupture associated with treatment with quinolone antibiotics,
• Subjects with, or with a history of, additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia), or a family history of long QT syndrome or family history of sudden death.